Proteintech Selects AWS as Preferred Cloud Provider, Launches Industry’s First AI Antibody Assistant to Accelerate Scientific Discovery

LAS VEGAS-December 4, 2025-Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Proteintech, a global leader in antibody and life science solutions, has selected AWS as its preferred cloud provider. Using AWS's compute, containers, database, and analytics services, Proteintech successfully built the industry's first AI antibody assistant called "Able" in just six months. This tool provides researchers with precise, efficient product information and technical support to accelerate scientific discovery and innovation.

Proteintech's core business includes the production and sale of antibodies, nanobodies, proteins, kits and other reagents, serving global academic and pharmaceutical customers with proteomics, cell culture, and current Good Manufacturing Practice (cGMP) biomanufacturing applications. Proteintech has migrated 85% of its workloads to AWS, leveraging AWS's secure, reliable, and highly available infrastructure to achieve integrated operations across its headquarters and global subsidiaries, accelerating global business deployment and expansion.

Driven by the mission to "provide researchers worldwide with precise and efficient product information and technical support to enable scientific discovery and innovation," Proteintech created this AI experimental assistant dedicated to life science researchers. Able shares Proteintech's product data, experimental data, and relevant scientific knowledge, allowing scientists to obtain product recommendations and experimental design support through conversational interactions, enabling them to focus more on cutting-edge research and drive scientific innovation. Using AWS's elastic cloud computing resources, Proteintech significantly optimized the entire process from project initiation and selection to development and testing, reducing Able's launch cycle by 50% and gaining a first-mover advantage in AI application development.

With AWS, Proteintech effectively reduced Able's operational costs while improving stability. Built on Amazon Elastic Compute Cloud (Amazon EC2), Able can flexibly scale up or down during business peaks, achieving elastic scaling of computing resources and effectively reducing computing costs. With Amazon Elastic Container Service (Amazon ECS), Proteintech can uniformly manage Able's inference, web gateway, vector retrieval, and other microservices, ensuring zero-downtime version updates. Using ECS Task Placement strategies, Proteintech effectively addresses complex requirements of different workloads, providing researchers with a stable and reliable intelligent assistant.

Using AWS's managed relational database and petabyte-scale cloud data warehouse services, Able can quickly extract useful scientific information from massive data, improving research efficiency. Able stores structured business data using Amazon Relational Database Service (Amazon RDS) and is deployed with Amazon RDS Multi-AZ, making it easy to complete time-consuming database management tasks while ensuring high data availability. At the same time, Able uses Amazon Redshift to build a research behavior data warehouse, enabling scientists to directly leverage its SQL analysis capabilities to perform large-scale cross-analysis of data such as Amazon RDS SQL Server logs and experimental result files, accessing expert-level R&D assistance in a very short time.

"Proteintech has successfully built the industry's first AI antibody assistant 'Able' based on AWS, accelerating life science research efficiency by providing intelligent, precise scientific Q&A services," said Ma Li, IT vice president of Proteintech Group. "In the future, we will continue to explore more innovative application scenarios with AWS to enable breakthroughs in life science research."

"We are proud to support Proteintech in their mission to empower scientists with an intelligent AI research assistant that accelerates discovery and fuels innovation in life sciences," said Jared Saul, chief medical officer, Commercial Healthcare and Life Sciences at AWS. "AWS is the most secure, compliant, and resilient cloud for life sciences. We're pleased to enable Proteintech with leading cloud services and generative AI technology to help scientists accelerate biomarker discovery, improve research efficiency, and drive breakthrough scientific discoveries in the field of life sciences."